Abstract
Bevacizumab is a monoclonal antibody directed against Vascular Endothelial Growth Factor (VEGF). Evidence about its efficacy in addition to first-line chemotherapy in non-small-cell-lung-cancer (NSCLC) has been produced by two large randomized phase III clinical trials (ECOG 4599 and AVAiL), conducted in a clinically selected population with non-squamous histology and without major risk factors for bleeding. In the ECOG 4599 trial, the addition of bevacizumab (15 mg/kg) to carboplatin plus paclitaxel produced a statistically significant and clinically relevant improvement in overall survival (OS), that was the primary endpoint of the trial (12.3 months vs 10.3 months, HR 0.79; p=0.003). Furthermore, patients receiving bevacizumab showed a significant improvement in progression-free survival (PFS) and in objective response rates. Treatment with bevacizumab was well tolerated by the majority of patients, but was still associated with increased risk of clinically significant bleeding (4.4% vs 0.7%, p0.001). In the AVAiL trial the addition of bevacizumab (at the dose of 7.5 and 15 mg/kg) to cisplatin plus gemcitabine produced a small improvement in PFS, but no differences in OS. Information from retrospective analysis and two large observational studies (SAIL and ARIES) have confirmed the safety profile of first-line bevacizumab with a wide range of chemotherapy partners, but whether its efficacy is comparable when combined with the different regimens is still unknown. The identification of predictive factors of efficacy would be relevant for the optimal use of the drug, but to date we have no conclusive data in this direction.
Keywords: Bevacizumab, VEGF, angiogenesis, NSCLC, clinical, monoclonal, Vascular Endothelial Growth Factor (VEGF), paclitaxel, gemcitabine
Current Medicinal Chemistry
Title: Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues
Volume: 19 Issue: 7
Author(s): C. Sandomenico, R. Costanzo, G. Carillio, M. C. Piccirillo, A. Montanino, M. Di Maio, G. Rocco, N. Normanno, F. Perrone and A. Morabito
Affiliation:
Keywords: Bevacizumab, VEGF, angiogenesis, NSCLC, clinical, monoclonal, Vascular Endothelial Growth Factor (VEGF), paclitaxel, gemcitabine
Abstract: Bevacizumab is a monoclonal antibody directed against Vascular Endothelial Growth Factor (VEGF). Evidence about its efficacy in addition to first-line chemotherapy in non-small-cell-lung-cancer (NSCLC) has been produced by two large randomized phase III clinical trials (ECOG 4599 and AVAiL), conducted in a clinically selected population with non-squamous histology and without major risk factors for bleeding. In the ECOG 4599 trial, the addition of bevacizumab (15 mg/kg) to carboplatin plus paclitaxel produced a statistically significant and clinically relevant improvement in overall survival (OS), that was the primary endpoint of the trial (12.3 months vs 10.3 months, HR 0.79; p=0.003). Furthermore, patients receiving bevacizumab showed a significant improvement in progression-free survival (PFS) and in objective response rates. Treatment with bevacizumab was well tolerated by the majority of patients, but was still associated with increased risk of clinically significant bleeding (4.4% vs 0.7%, p0.001). In the AVAiL trial the addition of bevacizumab (at the dose of 7.5 and 15 mg/kg) to cisplatin plus gemcitabine produced a small improvement in PFS, but no differences in OS. Information from retrospective analysis and two large observational studies (SAIL and ARIES) have confirmed the safety profile of first-line bevacizumab with a wide range of chemotherapy partners, but whether its efficacy is comparable when combined with the different regimens is still unknown. The identification of predictive factors of efficacy would be relevant for the optimal use of the drug, but to date we have no conclusive data in this direction.
Export Options
About this article
Cite this article as:
Sandomenico C., Costanzo R., Carillio G., C. Piccirillo M., Montanino A., Di Maio M., Rocco G., Normanno N., Perrone F. and Morabito A., Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues, Current Medicinal Chemistry 2012; 19 (7) . https://dx.doi.org/10.2174/092986712799320673
DOI https://dx.doi.org/10.2174/092986712799320673 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Methods for Biomarker Verification and Assay Development
Current Proteomics Palladium (II) Complex Enhances ROS-Dependent Apoptotic Effects <i>via</i> Autophagy Inhibition and Disruption of Multiple Signaling Pathways in Colorectal Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Role of microRNAs in Chronic Lymphocytic Leukemia Pathogenesis
Current Medicinal Chemistry CD44 and EpCAM: Cancer-Initiating Cell Markers
Current Molecular Medicine Emerging Vascular Risk Factors in Women: Any Differences from Men?
Current Medicinal Chemistry Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment
Current Medicinal Chemistry Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets Update on the Development of microRNA and siRNA Molecules as Regulators of Cell Physiology
Recent Patents on DNA & Gene Sequences Therapeutic Strategy of Advanced Hepatocellular Carcinoma by Using Combined Intra-Arterial Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Hypoxic Regulation of Metastasis via Hypoxia-Inducible Factors
Current Molecular Medicine Chemomodulating Effects of Flavonoids in Human Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain
Current Neuropharmacology Experimental and Computational Approaches to Improve Binding Affinity in Chemical Biology and Drug Discovery
Current Topics in Medicinal Chemistry In vivo Distribution of Tiotropium in a Rodent Model Utilizing AP-SMALDI Mass Spectrometry Imaging
Current Analytical Chemistry Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Novel Insight into Differential Gene Expression and Clinical Significance of Dopamine Receptors, COMT, and IL6 in BPH and Prostate Cancer
Current Molecular Medicine Curcumin Suppresses Tumor Growth and Angiogenesis in Human Glioma Cells Through Modulation of Vascular Endothelial Growth Factor/ Angiopoietin-2/Thrombospondin-1 Signaling
CNS & Neurological Disorders - Drug Targets microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology Fluorescence Studies of Anti-Cancer Drugs - Analytical and Biomedical Applications
Current Drug Targets